Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 12;5(3):221-227.
doi: 10.15326/jcopdf.5.3.2018.0150.

Impact of the IMPACT Trial

Ron Balkissoon  1
Affiliations

Impact of the IMPACT Trial

Ron Balkissoon. Chronic Obstr Pulm Dis. .
No abstract available

PubMed Disclaimer

Comment on

  • Once-Daily Single-Inhaler Triple Versus Dual Therapy in Patients with COPD
  • Single-inhaler Triple Therapy in Symptomatic COPD Patients: FULFIL Subgroup Analyses
  • Intensified Therapy with Inhaled Corticosteroids and Long-Acting β2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial
  • Corticosteroid Suppression of Antiviral Immunity Increases Bacterial Loads and Mucus Production in COPD Exacerbations
  • Role of Eosinophils in Airway Inflammation of Chronic Obstructive Pulmonary Disease

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management and prevention of COPD, 2018. GOLD website. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revi... Published 2018 Accessed July 2018.
    1. Bremner PR,Birk R,Brealey N,Ismaila AS,Zhu C-Q,Lipson DA. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1):19. doi: https://doi.org/10.1186/s12931-018-0724-0 - PMC - PubMed
    1. Wedzicha JA,Banerji D,Chapman KR,et al. (for the FLAME Investigators). Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222-2234. doi: https://doi.org/10.1056/NEJMoa1516385 - PubMed
    1. Cazzola M,Ora J,Puxeddu E. Dual bronchodilation and exacerbations of COPD. J Thorac Dis. 2016;8(9):2383-2386. doi: https://doi.org/10.21037/jtd.2016.08.92 - PMC - PubMed
    1. Bourbeau J,Aaron SD,Barnes NC,Davis KJ,Lacasse Y,Nadeau G. Evaluating the risk of pneumonia with inhaled corticosteroids in COPD: retrospective database studies have their limitations SA. Respir Med. 2017;123:94-97. doi: https://doi.org/10.1016/j.rmed.2016.12.015 - PubMed

LinkOut - more resources